SS-31

SS-31 is a mitochondria-targeted tetrapeptide, one of the Szeto-Schiller peptides, and is also known by the development names elamipretide and Bendavia ^[2]. It is an aromatic-cationic peptide that selectively concentrates in the inner mitochondrial membrane, where it binds the unique phospholipid cardiolipin, and it is described as the first-in-class cardiolipin-protective compound ^[1][2]. Unlike broad antioxidants, it localizes precisely to the site of energy production, which is central to its pharmacology ^[1][2].

Its research and clinical applications focus on conditions rooted in mitochondrial dysfunction. Preclinical work established that SS-31 re-energizes ischemic mitochondria and protects the cristae membranes needed for ATP synthesis, reducing tissue damage in models of ischemia-reperfusion injury ^[1]. Reviews describe a broad therapeutic program spanning heart failure, ischemia-reperfusion injury, mitochondrial myopathies, and the energy decline of aging, since restoring mitochondrial bioenergetics offers a shared strategy across these diseases ^[2]. Biophysical studies have further clarified how the peptide interacts with membranes and modulates surface electrostatics as a key part of its mechanism ^[3], and structure-activity work has benchmarked analogues against SS-31 to guide next-generation designs ^[4].

Elamipretide has been evaluated in human clinical trials for primary mitochondrial disease, heart failure, and other conditions, and while it remains investigational rather than broadly approved, it is one of the most clinically advanced mitochondrial therapeutics ^[1][2]. It is administered by injection as a peptide. Its enduring appeal is the concept of a targeted compound that docks onto cardiolipin to stabilize the electron transport machinery and recharge the cell's power supply, addressing a fundamental defect that underlies many complex and age-related diseases ^[1][2].

SS-31 (elamipretide) is an investigational mitochondria-targeting peptide studied in trials for mitochondrial and cardiac diseases; it is not an approved drug. In studies the most commonly reported adverse effects were injection-site reactions. Its long-term safety and any benefit for longevity or performance in healthy people remain unproven.

MDS-31 is chemically identical to SS-31, one of the Szeto-Schiller (SS) peptides developed in the early 2000s by Hazel Szeto and Peter Schiller at Weill Cornell Medical College while searching for cell-permeable, mitochondria-targeting antioxidants. Researchers subsequently found that SS-31 concentrates at the inner mitochondrial membrane and binds selectively to the phospholipid cardiolipin, which reframed it as a first-in-class cardiolipin-protective compound rather than a simple radical scavenger.

Under the development names MTP-131, Bendavia, and later elamipretide, the peptide was advanced into human trials by Stealth BioTherapeutics for conditions ranging from primary mitochondrial myopathy to heart failure and inherited eye disease. A phase 1/2 study (MMPOWER) reported dose-dependent gains on the six-minute walk test in adults with primary mitochondrial myopathy, establishing an early human efficacy signal for the molecule.

MDS-31 is regarded as one of the most scientifically pedigreed entries in the mitochondrial peptide space, since it shares its structure with a compound carried through multiple registered clinical trials. Its appeal rests on an unusually well-defined mechanism; few longevity-adjacent compounds can point to a specific molecular target as concrete as cardiolipin at the inner mitochondrial membrane.

Preclinical work in aged animals showing restored ATP production and improved endurance has kept interest high among those focused on cellular energy and healthy aging. At the same time, observers note honestly that later-stage human trials produced mixed results, with a large phase 3 program missing its overall primary endpoint while suggesting benefit in genetically defined subgroups. That combination of a clear mechanism, encouraging early signals, and unresolved late-stage questions defines its current standing.